These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 28677065)
1. Ferumoxytol-enhanced magnetic resonance angiography for the assessment of potential kidney transplant recipients. Stoumpos S; Hennessy M; Vesey AT; Radjenovic A; Kasthuri R; Kingsmore DB; Mark PB; Roditi G Eur Radiol; 2018 Jan; 28(1):115-123. PubMed ID: 28677065 [TBL] [Abstract][Full Text] [Related]
2. Minimizing table time in patients with claustrophobia using focused ferumoxytol-enhanced MR angiography ( Shahrouki P; Nguyen KL; Moriarty JM; Plotnik AN; Yoshida T; Finn JP Br J Radiol; 2021 Sep; 94(1125):20210430. PubMed ID: 34415199 [TBL] [Abstract][Full Text] [Related]
3. Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease. Stoumpos S; Hennessy M; Vesey AT; Radjenovic A; Kasthuri R; Kingsmore DB; Mark PB; Roditi G Eur Radiol; 2019 Jul; 29(7):3543-3552. PubMed ID: 30919067 [TBL] [Abstract][Full Text] [Related]
4. MR Angiography of Renal Transplant Vasculature with Ferumoxytol:: Comparison of High-Resolution Steady-State and First-Pass Acquisitions. Corwin MT; Fananapazir G; Chaudhari AJ Acad Radiol; 2016 Mar; 23(3):368-73. PubMed ID: 26707344 [TBL] [Abstract][Full Text] [Related]
5. Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent. Bashir MR; Jaffe TA; Brennan TV; Patel UD; Ellis MJ Transplantation; 2013 Jul; 96(1):91-6. PubMed ID: 23680931 [TBL] [Abstract][Full Text] [Related]
6. Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Luhar A; Khan S; Finn JP; Ghahremani S; Griggs R; Zaritsky J; Salusky I; Hall TR Pediatr Radiol; 2016 Aug; 46(9):1332-40. PubMed ID: 27059620 [TBL] [Abstract][Full Text] [Related]
7. High resolution, 3-dimensional Ferumoxytol-enhanced cardiovascular magnetic resonance venography in central venous occlusion. Shahrouki P; Moriarty JM; Khan SN; Bista B; Kee ST; DeRubertis BG; Yoshida T; Nguyen KL; Finn JP J Cardiovasc Magn Reson; 2019 Mar; 21(1):17. PubMed ID: 30853026 [TBL] [Abstract][Full Text] [Related]
8. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. Li W; Tutton S; Vu AT; Pierchala L; Li BS; Lewis JM; Prasad PV; Edelman RR J Magn Reson Imaging; 2005 Jan; 21(1):46-52. PubMed ID: 15611942 [TBL] [Abstract][Full Text] [Related]
9. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196 [TBL] [Abstract][Full Text] [Related]
10. Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography. Stabi KL; Bendz LM Ann Pharmacother; 2011 Dec; 45(12):1571-5. PubMed ID: 22045905 [TBL] [Abstract][Full Text] [Related]
11. Ferumoxytol-enhanced magnetic resonance angiography provides comparable vascular conspicuity to CT angiography in dogs with intrahepatic portosystemic shunts. Wilson S; Culp WTN; Wisner ER; Cissell DD; Finn JP; Zwingenberger AL Vet Radiol Ultrasound; 2021 Jul; 62(4):463-470. PubMed ID: 33634935 [TBL] [Abstract][Full Text] [Related]
12. Transplant renal artery and vein occlusion evaluated with ferumoxytol-enhanced magnetic resonance angiography. Aghayev A; Memon AA; Zheng S; Menard M; Siedlecki AM Clin Imaging; 2021 Sep; 77():142-146. PubMed ID: 33684787 [TBL] [Abstract][Full Text] [Related]
13. The use of ferumoxytol for high-resolution vascular imaging and troubleshooting for abdominal allografts. Shah A; Neitzel E; Panda A; Fananapazir G Abdom Radiol (NY); 2024 Aug; 49(8):2858-2872. PubMed ID: 38561553 [TBL] [Abstract][Full Text] [Related]
14. Emerging applications for ferumoxytol as a contrast agent in MRI. Bashir MR; Bhatti L; Marin D; Nelson RC J Magn Reson Imaging; 2015 Apr; 41(4):884-98. PubMed ID: 24974785 [TBL] [Abstract][Full Text] [Related]
15. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease. Walker JP; Nosova E; Sigovan M; Rapp J; Grenon MS; Owens CD; Gasper WJ; Saloner DA Ann Vasc Surg; 2015 Jan; 29(1):63-8. PubMed ID: 25269682 [TBL] [Abstract][Full Text] [Related]
16. Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. Ruangwattanapaisarn N; Hsiao A; Vasanawala SS Pediatr Radiol; 2015 Jun; 45(6):831-9. PubMed ID: 25427433 [TBL] [Abstract][Full Text] [Related]
17. Vascular Imaging With Ferumoxytol as a Contrast Agent. Hope MD; Hope TA; Zhu C; Faraji F; Haraldsson H; Ordovas KG; Saloner D AJR Am J Roentgenol; 2015 Sep; 205(3):W366-73. PubMed ID: 26102308 [TBL] [Abstract][Full Text] [Related]
18. Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases. Bashir MR; Mody R; Neville A; Javan R; Seaman D; Kim CY; Gupta RT; Jaffe TA J Magn Reson Imaging; 2014 Jul; 40(1):113-8. PubMed ID: 24130008 [TBL] [Abstract][Full Text] [Related]
19. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256 [TBL] [Abstract][Full Text] [Related]
20. Ferumoxytol-enhanced MRI in the peripheral vasculature. Lehrman ED; Plotnik AN; Hope T; Saloner D Clin Radiol; 2019 Jan; 74(1):37-50. PubMed ID: 29731126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]